These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22420757)

  • 1. Biologics in oral medicine: principles of use and practical considerations.
    O'Neill ID; Scully C
    Oral Dis; 2012 Sep; 18(6):525-36. PubMed ID: 22420757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics, an alternative therapeutic approach for oral lichen planus.
    Zhang J; Zhou G; Du GF; Xu XY; Zhou HM
    J Oral Pathol Med; 2011 Aug; 40(7):521-4. PubMed ID: 21463368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When is switching warranted among biologic therapies in rheumatoid arthritis?
    Reynolds A; Koenig AS; Bananis E; Singh A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):319-33. PubMed ID: 22812556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune system and new therapies for inflammatory joint disease.
    Oliver SM
    Musculoskeletal Care; 2003 Mar; 1(1):44-57. PubMed ID: 20217663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic Therapies: Anti-Tumor Necrosis Factor-α, Anti-Interleukins, Rituximab and Others.
    Bhatt N; Tucker W; Sen HN; Nussenblatt RB
    Dev Ophthalmol; 2016; 55():252-64. PubMed ID: 26501216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics in oral medicine: ulcerative disorders.
    O'Neill ID; Scully C
    Oral Dis; 2013 Jan; 19(1):37-45. PubMed ID: 22471882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Future perspectives in the treatment of psoriasis: news in biological therapies].
    Diamantino F; Ferreira A
    Acta Med Port; 2011; 24(6):997-1004. PubMed ID: 22713194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The multidisciplinary practice guideline "The responsible use of biologicals"].
    Bijlsma JW; Hagemeijer JW; Bijl M; Jansen TL; van de Laar MA; Landewé RB; Nurmohamed MT
    Ned Tijdschr Geneeskd; 2011; 155(30-31):A3114. PubMed ID: 22085508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of biological agents in the treatment of psoriasis.
    Rongioletti F; Burlando M; Parodi A
    Am J Clin Dermatol; 2010; 11 Suppl 1():35-7. PubMed ID: 20586505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of biologicals in the management of inflammatory oral mucosal disease.
    O'Neill ID
    J Oral Pathol Med; 2008 Nov; 37(10):575-81. PubMed ID: 18764859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach.
    Goodfield M
    Br J Dermatol; 2012 Nov; 167 Suppl 3():21-6. PubMed ID: 23082812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing treatment with biologics.
    Mader R; Keystone E
    J Rheumatol Suppl; 2007 Nov; 80():16-24. PubMed ID: 17985419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to manage infections in the era of biologics?
    Saraceno R; Chimenti S
    Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics and infections: lessons from tumor necrosis factor blocking agents.
    Wallis RS
    Infect Dis Clin North Am; 2011 Dec; 25(4):895-910. PubMed ID: 22054762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis.
    Kuroda T; Tanabe N; Kobayashi D; Sato H; Wada Y; Murakami S; Saeki T; Nakano M; Narita I
    J Rheumatol; 2012 Jul; 39(7):1348-54. PubMed ID: 22589255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What have we learned in dermatology from the biologic therapies?
    Nickoloff BJ; Stevens SR
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S143-51. PubMed ID: 16488330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.